Medtronic

SMART 2-year TAVR hemodynamic data: Medtronic Evolut is better compared to Edwards Sapien in small annulus patients
Howard Herrmann, MD, MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.
Physicians are leaning into supra-annular, self-expanding TAVR valves for women and small-annulus patients
"The onus is on us as cardiologists to make sure we offer the very best possible devices for our patients with the available data that we have," interventional cardiologist Anene Ukaigwe, MD, explained.
Women with severe aortic stenosis remain underdiagnosed, undertreated—here’s how cardiologists can make a difference
Women with cardiovascular disease are consistently underdiagnosed and undertreated compared to men, and those disparities are true for aortic stenosis as well. Women with symptomatic severe AS are up to 35% less likely than men to undergo aortic valve replacement, for example, and they often have to wait longer just to be referred for further care.
TAVR technology keeps evolving, improving outcomes without compromising valve performance
TAVR is a go-to treatment for symptomatic severe aortic stenosis in much of the world, thanks in large part to the hard work of research teams that never stop looking for new, innovative ways to make the technology more effective.
Q&A: How supra-annular, self-expanding TAVR valves open up options for future interventions
TAVR procedures have surged more than 30% since 2020, with more than 107,000 patients receiving a new prosthetic valve in 2023 alone. As this trend continues, it’s increasingly important that cardiologists consider the long-term impact on future coronary interventions patients may need.

‘A huge victory for patient care’: Next-gen TAVR valve helps cardiologists target more patients

“The Evolut FX system is an improvement over previous Evolut system devices and it delivers better overall results to our patients,” says interventional cardiologist Guilherme Attizzani, MD. “It is an ideal solution for a majority of our patients.”

Structural heart clinics see key benefits from improved referral tracking

Identifying patients with severe aortic stenosis who could potentially benefit from transcatheter aortic valve replacement (TAVR) is very important—but managing and tracking them over time can be quite a challenge.

Data mining helps hospitals identify new patients in need of TAVR, other structural heart procedures

When the ACC and AHA collaborated on new valvular heart disease guidelines in 2020, the two groups highlighted the importance of interventional treatment options such as TAVR. However, an estimated one-third of patients with severe aortic stenosis in the U.S. still lack a guideline-recommended treatment plan.

Underdiagnosed and undertreated: How cardiologists and primary care physicians are working together to identify patients with severe aortic stenosis

Aortic stenosis (AS) is one of the most common—and growing—cardiac conditions. In particular, the prevalence of severe AS rises markedly among elderly Americans, affecting an estimated 3.4% of Americans 75 and older.[1]

Q&A: What the impressive durability of self-expanding TAVR valves means for patient care, shared decision-making

Updates about transcatheter aortic valve replacement (TAVR) are always big news, but the new five-year data from the CoreValve™ US Pivotal and SURTAVI trials came as a welcome surprise to many cardiologists.

Same-day Discharge for PCI: WellStar Embraces Consistency, Culture and ‘the Human Side of Care’

The trend to get PCI patients out of the hospital safely on the same day as their procedure has long been a goal for many health systems. WellStar Kennestone Regional Hospital, part of WellStar Health System in Atlanta, made same-day discharge for a vast majority of PCI patients a mission three years ago.

Reducing CIED Infections and the Cost of Care: Lessons from Cleveland Clinic

Thinking has changed: Cardiac implantable electronic device (CIED) infections are a bigger deal than we thought.

Q&A U.S. and European Valvular Heart Disease Guidelines: Lessons from Across the Pond

“Good harmony” is the way John P. Erwin III, MD, describes the synergy of the 2021 ESC/EACTS Guidelines for the management of valvular heart disease (VHD) released in August along with the ACC/AHA guidelines that rolled in December 2020.

Medtronic

SMART 2-year TAVR hemodynamic data: Medtronic Evolut is better compared to Edwards Sapien in small annulus patients

Physicians are leaning into supra-annular, self-expanding TAVR valves for women and small-annulus patients

Women with severe aortic stenosis remain underdiagnosed, undertreated—here’s how cardiologists can make a difference

TAVR technology keeps evolving, improving outcomes without compromising valve performance

Q&A: How supra-annular, self-expanding TAVR valves open up options for future interventions